PepGenexShop our research products

KPV

Also identified as Lys-Pro-Val, α-MSH (11-13)

Tripeptide, α-MSH (11-13)

Sequence: Lys-Pro-Val

Molecular weight
342.4
Molecular formula
C16H30N4O4
CAS
67727-97-3
Published studies reviewed
6

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE. NOT FOR HUMAN CONSUMPTION.

Compounds described on this site are supplied solely for laboratory research. They are not offered for human or veterinary use or for clinical use, and they are not intended to diagnose, mitigate, cure or prevent any disease.

KPV is the tripeptide Lys-Pro-Val, matching residues 11 to 13 of alpha-melanocyte-stimulating hormone. The six publications reviewed are cell-culture and mouse studies of transporter uptake, NF-κB signalling and chemically induced colon inflammation, along with an older antimicrobial report and a later letter that could not reproduce part of it. No human study was identified, and nanoparticle or hydrogel formulations and related derivatives are left out as different materials.

At a glance

Also identified as
Lys-Pro-Val, α-MSH (11-13)
Class
Tripeptide, α-MSH (11-13)
Target or mechanism
PepT1 di/tripeptide transporter (uptake); NF-κB signalling (p65RelA nuclear import, in one cell line)
Evidence types represented
in vitro, animal
Published studies reviewed
6
Last reviewed
2026-09-21

Overview

KPV is the three C-terminal residues of alpha-melanocyte-stimulating hormone — lysine, proline, valine — which is itself cut from the pro-opiomelanocortin precursor (UniProt P01189).

The publications on this page are cell-culture and mouse studies. They describe how the tripeptide enters cells, what it does to one signalling pathway in human epithelial and immune cell lines, and what happens in two chemically induced mouse models of colon inflammation. One older in vitro antimicrobial report is recorded together with a later letter in the same journal reporting a failure to reproduce part of it.

No human study of this tripeptide was identified in a PubMed search on 21 September 2026. Nothing on this page is a human finding.

Not recorded on this page: papers in which KPV is carried inside nanoparticles or a hydrogel, and papers on the related peptides KP-D-V, KdPT and [Ac-CKPV]2. A formulation and a derivative are each a different material from the tripeptide itself.

Mechanism under investigation

KPV
  • PepT1 di/tripeptide transporter (uptake)
  • NF-κB signalling (p65RelA nuclear import, in one cell line)

The sources recorded here describe the tripeptide entering cells through the PepT1 di/tripeptide transporter and, in human cell lines, acting inside the cell on NF-κB signalling — one of them locating the interaction at the importin-α3 binding site on p65RelA. A keratinocyte study found no rise in cyclic AMP with this tripeptide, and one mouse study reports its effect persisting in animals whose melanocortin-1 receptor is non-functional. No source here establishes a receptor the tripeptide binds.

Scope of the published work

Areas investigated
  • Transporter-mediated uptake
  • NF-κB and MAP kinase signalling
  • Colon inflammation in mice
  • Antimicrobial activity in vitro
  • Melanocortin receptor signalling
Models used
  • Human intestinal epithelial and T-cell lines
  • Human keratinocytes and transfected CHO cells
  • Immortalised human bronchial epithelial cells
  • Mouse colitis models
  • Bacterial and yeast cultures

Every figure on this page comes from a cell-culture or animal study, using material prepared for that study. It is not the research material PepGenex supplies and no result here transfers to it, or to people.

Limitations

Evidence represented on this page: in vitro and animal. No human research is represented. The page reviews 6 published studies, and each figure is reported for the study that published it; results are not pooled across studies. 2 of these publications carry a note on whether they studied this exact material.

Common questions

What is KPV?

KPV is the three C-terminal residues of alpha-melanocyte-stimulating hormone — lysine, proline, valine — which is itself cut from the pro-opiomelanocortin precursor (UniProt P01189).

How does KPV work, according to the published research?

The sources recorded here describe the tripeptide entering cells through the PepT1 di/tripeptide transporter and, in human cell lines, acting inside the cell on NF-κB signalling — one of them locating the interaction at the importin-α3 binding site on p65RelA. A keratinocyte study found no rise in cyclic AMP with this tripeptide, and one mouse study reports its effect persisting in animals whose melanocortin-1 receptor is non-functional. No source here establishes a receptor the tripeptide binds.

  • In immortalised human bronchial epithelial cells (16HBE14o-) stimulated with TNFα or respiratory syncytial virus, KPV produced a concentration-dependent inhibition of NF-κB reporter activity, matrix metalloproteinase-9 activity and IL-8 and eotaxin secretion. The KPV effect was associated with the peptide's own nuclear import, stabilisation of IκBα and suppressed nuclear translocation of YFP-tagged p65RelA, and competition assays indicated an interaction between KPV and the importin-α3 binding site on p65RelA. (Land, 2012, PMID 22837805)
  • No elevation of cyclic AMP was detected in HaCaT cells or in normal human keratinocytes in response to α-MSH, KPV or ACTH peptides, although the anti-inflammatory action of α-MSH had been assumed to be cyclic-AMP dependent. (Elliott et al., 2004, PMID 15102092)
  • Reports that α-MSH (1-13) and its C-terminal tripeptide KPV, tested together as 'α-MSH peptides', significantly inhibited Staphylococcus aureus colony formation and reduced the viability and germ-tube formation of Candida albicans, over a broad concentration range including the picomolar. Cellular cAMP was significantly higher in the yeast after exposure and the adenylyl cyclase inhibitor dideoxyadenosine partly reversed the killing, which the authors read as cAMP involvement. The peptides did not lower killing of either organism by human neutrophils. (Cutuli et al., 2000, PMID 10670585)

What has published research on KPV found, and what are its limits?

This page records 6 publications, reporting laboratory (in vitro) work in 5, animal work in 2. Each is listed with its identifier under References.

No human study is represented on this page.

Evidence represented on this page: in vitro and animal.

No human research is represented.

The page reviews 6 published studies, and each figure is reported for the study that published it; results are not pooled across studies.

2 of these publications carry a note on whether they studied this exact material.

Every figure on this page comes from a cell-culture or animal study, using material prepared for that study. It is not the research material PepGenex supplies and no result here transfers to it, or to people.

Is KPV approved by the U.S. FDA?

This page cites no FDA approval record for KPV; PepGenex Science states a U.S. regulatory status only where a sourced record exists.

PepGenex research materials are not FDA approved and are not for human or veterinary use.

What risks have published studies of KPV reported?

No human study is recorded on this page, so it reports no adverse events in people. Laboratory and animal findings are not a measure of risk in people.

Published research

Grouped by the kind of study. Select one to narrow what is shown below.

Laboratory (in vitro)(4)

Laboratory (in vitro)

Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.

Land SC., International Journal of Physiology, Pathophysiology and Pharmacology, 2012;4(2):59-73

published

  • In immortalised human bronchial epithelial cells (16HBE14o-) stimulated with TNFα or respiratory syncytial virus, KPV produced a concentration-dependent inhibition of NF-κB reporter activity, matrix metalloproteinase-9 activity and IL-8 and eotaxin secretion. The KPV effect was associated with the peptide's own nuclear import, stabilisation of IκBα and suppressed nuclear translocation of YFP-tagged p65RelA, and competition assays indicated an interaction between KPV and the importin-α3 binding site on p65RelA.
  • In the same cells, the comparison peptide γ-MSH required the melanocortin-3 receptor for its effect while the KPV effect did not, which the author presents as two separate routes to suppressing NF-κB signalling in this epithelium.
View publication →
Laboratory (in vitro)

Anti-Candida activity of alpha-melanocyte-stimulating hormone (alpha-MSH) peptides.

Rauch I, Holzmeister S, Kofler B., Journal of Leukocyte Biology, 2009;85(3):371-372; author reply 373

published (letter; comment on J Leukoc Biol 2000;67(2):233-9)

Material identity not established. This is a letter about alpha-MSH peptides, published as a comment on the antimicrobial study above. Its abstract names alpha-MSH for the assays it ran and does not state separately whether the tripeptide itself was retested, so it is recorded here as a challenge to the antimicrobial finding rather than as a study of this tripeptide.

  • A letter in the same journal reports microplate-based growth-inhibition assays on Candida albicans in which no growth-inhibiting effect was observed; on repeating the originally published assay with different C. albicans strains, the authors report detecting only a mild growth-inhibiting effect at 100 µM. The letter was published with a reply from the original authors, which this project has not read.
Limitations

The antimicrobial report and the letter disputing it are both recorded here because neither settles the matter. The original tested α-MSH and the tripeptide as a group; the letter reports a failure to reproduce the anti-Candida effect and was answered by the original authors in the same issue. Read the pair, not either one alone.

View publication →
Laboratory (in vitro)

alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.

Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW., Journal of Investigative Dermatology, 2004;122(4):1010-1019

published

  • No elevation of cyclic AMP was detected in HaCaT cells or in normal human keratinocytes in response to α-MSH, KPV or ACTH peptides, although the anti-inflammatory action of α-MSH had been assumed to be cyclic-AMP dependent.
  • Rapid, acute rises in intracellular calcium were observed in HaCaT keratinocytes in response to α-MSH, KPV, KP-D-V and ACTH across 10⁻¹⁵ to 10⁻⁷ M, but only in the presence of PIA, an adenosine agonist that inhibits the cyclic AMP pathway. In Chinese hamster ovary cells stably transfected with the melanocortin-1 receptor, the authors report that α-MSH and the KPV peptides — their term, covering both KPV and KP-D-V — elevated intracellular calcium.
Context

Three of these studies bear on the same open question: which route the tripeptide acts through. It is taken into cells by a peptide transporter; it did not raise cyclic AMP in keratinocytes; and its effect in mice persisted when the melanocortin-1 receptor was non-functional. That is a consistent picture of an intracellular action rather than a receptor one, and it is not the same thing as an identified target.

View publication →
Laboratory (in vitro)

Antimicrobial effects of alpha-MSH peptides.

Cutuli M, Cristiani S, Lipton JM, Catania A., Journal of Leukocyte Biology, 2000;67(2):233-239

published; comment and author reply, J Leukoc Biol 2009;85(3):371-2

Material identity not established. This study tested alpha-MSH (1-13) and its C-terminal tripeptide KPV together, and its abstract reports the antimicrobial results for 'alpha-MSH peptides' as a group. Which part of each result belongs to the tripeptide by itself is not established by the abstract.

  • Reports that α-MSH (1-13) and its C-terminal tripeptide KPV, tested together as 'α-MSH peptides', significantly inhibited Staphylococcus aureus colony formation and reduced the viability and germ-tube formation of Candida albicans, over a broad concentration range including the picomolar. Cellular cAMP was significantly higher in the yeast after exposure and the adenylyl cyclase inhibitor dideoxyadenosine partly reversed the killing, which the authors read as cAMP involvement. The peptides did not lower killing of either organism by human neutrophils.
Limitations

The antimicrobial report and the letter disputing it are both recorded here because neither settles the matter. The original tested α-MSH and the tripeptide as a group; the letter reports a failure to reproduce the anti-Candida effect and was answered by the original authors in the same issue. Read the pair, not either one alone.

View publication →

Preclinical (animal)(2)

Laboratory (in vitro)Preclinical (animal)

PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D., Gastroenterology, 2008;134(1):166-178

published

  • In human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and human T cells (Jurkat) stimulated with pro-inflammatory cytokines, nanomolar concentrations of KPV inhibited activation of NF-κB and of MAP kinase signalling and lowered pro-inflammatory cytokine secretion, measured by NF-κB luciferase reporter, Western blot, real-time RT-PCR and ELISA.
  • Uptake experiments using unlabelled KPV as a competitor for a radiolabelled PepT1 substrate, and tritiated KPV to measure uptake kinetics, led the authors to report that the tripeptide is transported into cells by PepT1, a di/tripeptide transporter expressed in the immune and intestinal epithelial cells studied.
  • In mice with colitis induced by dextran sodium sulfate and by TNBS, KPV added to drinking water lowered the incidence of colitis, assessed histologically and by pro-inflammatory cytokine mRNA expression. The abstract gives no per-group figures.
Limitations

Every record on this page is a cell-culture or mouse finding. A PubMed search on 21 September 2026 identified no human study of this tripeptide. Mouse colitis models and immortalised cell lines are where this compound has been characterised, and a result in either is a starting point for a question about people, not an answer to one.

Context

Three of these studies bear on the same open question: which route the tripeptide acts through. It is taken into cells by a peptide transporter; it did not raise cyclic AMP in keratinocytes; and its effect in mice persisted when the melanocortin-1 receptor was non-functional. That is a consistent picture of an intracellular action rather than a receptor one, and it is not the same thing as an identified target.

View publication →
Preclinical (animal)

Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.

Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Böhm M, Luger TA, Domschke W, Kucharzik T., Inflammatory Bowel Diseases, 2008;14(3):324-331

published

  • Examined the tripeptide in two mouse models of intestinal inflammation — dextran sodium sulfate colitis and CD45RB-high transfer colitis — following the course by body-weight change, colon histology and myeloperoxidase activity. In the dextran sodium sulfate model the authors report earlier recovery, significantly greater regain of body weight, significantly fewer inflammatory infiltrates on histology and significantly lower myeloperoxidase activity in colonic tissue; in the transfer model they report recovery, regain of body weight and fewer inflammatory changes on histology. The abstract reports no numeric values or p-values for any of these.
  • In mice expressing a non-functional melanocortin-1 receptor (MC1Re/e) given dextran sodium sulfate, the authors report that all animals in the KPV group survived, and conclude that the effects seem to be at least partly independent of melanocortin-1 receptor signalling.
Limitations

Every record on this page is a cell-culture or mouse finding. A PubMed search on 21 September 2026 identified no human study of this tripeptide. Mouse colitis models and immortalised cell lines are where this compound has been characterised, and a result in either is a starting point for a question about people, not an answer to one.

Context

Three of these studies bear on the same open question: which route the tripeptide acts through. It is taken into cells by a peptide transporter; it did not raise cyclic AMP in keratinocytes; and its effect in mice persisted when the melanocortin-1 receptor was non-functional. That is a consistent picture of an intracellular action rather than a receptor one, and it is not the same thing as an identified target.

View publication →

Compared with related compounds

Classification, structure, recorded targets, evidence types and FDA status only, each read from the two compounds' own pages. These comparisons do not compare study results.

KPV and PT-141

Melanocortin-related peptides: KPV is the α-MSH (11-13) tripeptide; PT-141 is a cyclic structural analogue of α-MSH.

KPVPT-141
ClassificationTripeptide, α-MSH (11-13)Cyclic heptapeptide
StructureSequence Lys-Pro-Val; formula C16H30N4O4Sequence Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys) (Asp–Lys side-chain lactam); formula C50H68N14O10
Targets recordedPepT1 di/tripeptide transporter (uptake); NF-κB signalling (p65RelA nuclear import, in one cell line)Agonist: Melanocortin 4 receptor (MC4R)
Evidence types representedin vitro, animalin vitro, human
Status with the U.S. FDANot shown (no Drugs@FDA application record verified for this page)An FDA approved drug product containing bremelanotide (PT-141) exists. Source: Drugs@FDA, Application NDA 210557.

References

Published studies reviewed (6)

  1. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. — Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D., Gastroenterology, 2008;134(1):166-178
    DOI 10.1053/j.gastro.2007.10.026 · PMID 18061177 · PMC2431115
  2. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. — Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Böhm M, Luger TA, Domschke W, Kucharzik T., Inflammatory Bowel Diseases, 2008;14(3):324-331
    DOI 10.1002/ibd.20334 · PMID 18092346
  3. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. — Land SC., International Journal of Physiology, Pathophysiology and Pharmacology, 2012;4(2):59-73
    PMID 22837805 · PMC3403564
  4. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. — Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW., Journal of Investigative Dermatology, 2004;122(4):1010-1019
    DOI 10.1111/j.0022-202X.2004.22404.x · PMID 15102092
  5. Antimicrobial effects of alpha-MSH peptides. — Cutuli M, Cristiani S, Lipton JM, Catania A., Journal of Leukocyte Biology, 2000;67(2):233-239
    DOI 10.1002/jlb.67.2.233 · PMID 10670585
  6. Anti-Candida activity of alpha-melanocyte-stimulating hormone (alpha-MSH) peptides. — Rauch I, Holzmeister S, Kofler B., Journal of Leukocyte Biology, 2009;85(3):371-372; author reply 373
    DOI 10.1189/jlb.1008614 · PMID 19092131

Continue learning